The Fat and the Furiex: Could FDA Wins Help Contrave Bid?
The FDA's marketing clearance of three alogliptin-containing drugs for Type II diabetes as adjuncts to diet and exercise sent Furiex Pharmaceuticals Inc. on a happy Wall Street ride, at the same time causing onlookers to speculate about what the approvals might mean for the obesity candidate Contrave, which like alogliptin is partnered with Takeda Pharmaceutical Co. Ltd.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter